Prothena Corporation plc (Nasdaq:PRTA) announced that an abstract was published by the XIV International Symposium on Amyloidosis (ISA) and described interim data from an ongoing Phase 1 study of NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction, as of the abstract submission date. Updated data will be presented for the first time at ISA in Indianapolis, Indiana. Prothena Corporation PLC (NASDAQ:PRTA) shares after opening at $33.44 moved to $41.33 on last trade day and at the end of the day closed at $36.95 . Company price to sales ratio in past twelve months was calculated as 735.64 and price to cash ratio as 7.94. Prothena Corporation PLC (NASDAQ:PRTA) showed a positive weekly performance of 40.71%.
MacroGenics, Inc. (NASDAQ:MGNX) announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART(R)) protein, has potent activity against colorectal cancer cells both in vitro and in vivo. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. MacroGenics Inc (NASDAQ:MGNX) shares advanced 7.50% in last trading session and ended the day on $20.65. MGNX return on equity ratio is recorded as -32.80% and its return on assets is -5.50 %.
US clinical-stage biopharma firm Epizyme Inc (Nasdaq:EPZM) announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase (HMT) targets in the company’s collaboration with UK pharma giant GlaxoSmithKline (LSE: GSK) and is receiving $4 million in milestone and license payments. Epizyme Inc (NASDAQ:EPZM) shares moved up 7.80% in last trading session and was closed at $ 23.35 while trading in range of $ 21.19 – $23.48 – Epizyme Inc (NASDAQ:EPZM) year to date (YTD) performance is 12.26 %.
CorMedix Inc. (NYSE:CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced the appointment of three new board members. CorMedix Inc. (NYSEMKT:CRMD) weekly performance is 24.39%. On last trading day company shares ended up $2.04. CorMedix Inc. (NYSEMKT:CRMD) distance from 50-day simple moving average (SMA50) is -13.66%. Analysts mean target price for the company is $24.39.